Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Neoplasms, Castration-Resistant × abiraterone × Clear all

Phase

Phase 2 3 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 11 Urogenital Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Bulbo-Spinal Atrophy, X-Linked 1 Adenocarcinoma 1

Interventions

enzalutamide 2 Prednisone 2 Abiraterone Acetate 2 tasquinimod 1 sabizabulin 1 niraparib 1 darolutamide 1 atezolizumab 1 abiraterone 1 Radiosurgery 1 Docetaxel 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04844749 2024-02-05

VERACITY

Veru Inc.

Phase 3 Terminated

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡